Paula T. Trzepacz
Corporate Officer/Principal bij The Indiana University School of Medicine
Profiel
Paula T.
Trzepacz is a Clinical Professor at The Indiana University School of Medicine, where she has been employed since 2004.
She previously served as the Chief Medical Officer & Executive Vice President at Neurotrope, Inc. and Synaptogenix, Inc. in 2016.
She was also a Professor at the University of Mississippi Medical Center and an Associate Professor at the University of Pittsburgh School of Medicine.
Trzepacz holds a doctorate from Dartmouth College and an undergraduate degree from Wellesley College.
Actieve functies van Paula T. Trzepacz
| Bedrijven | Functie | Begin |
|---|---|---|
| The Indiana University School of Medicine | Corporate Officer/Principal | 01-01-2004 |
Eerdere bekende functies van Paula T. Trzepacz
| Bedrijven | Functie | Einde |
|---|---|---|
| SYNAPTOGENIX, INC. | Hoofd Techniek/Wetenschap/O&O | 01-09-2016 |
| University of Mississippi Medical Center | Corporate Officer/Principal | - |
| University of Pittsburgh School of Medicine | Corporate Officer/Principal | - |
| NEUROTROPE, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Paula T. Trzepacz
| Wellesley College | Undergraduate Degree |
| Dartmouth College | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SYNAPTOGENIX, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Neurotrope, Inc.
 Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY. | Health Technology |
